Details for Patent: 10,137,127

Which drugs does patent 10,137,127 protect, and when does it expire?

Patent 10,137,127 protects VITRAKVI and is included in one NDA.

This patent has eighty-three patent family members in forty countries.

Summary for Patent: 10,137,127

Title:	Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Abstract:	A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.
Inventor(s):	Mark Reynolds, Steven A. Smith
Assignee:	Loxo Oncology Inc
Application Number:	US15/622,544
Patent Claim Types: see list of patent claims	Formulation; Compound;

Drugs Protected by US Patent 10,137,127

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 10,137,127

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	108090
Australia	2017246547
Australia	2017246554
Brazil	112018070017